Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Tesamorelin
EfficacyHigh
Studies8
Participants1,459
StatusAvailable

Tesamorelin

Growth Hormone-Releasing Hormone (1-44) amide

Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.

Clinical Benefits

Significant reduction in visceral abdominal fat (15.2% average)
FDA-approved treatment for HIV-associated lipodystrophy
Improved body composition and trunk-to-limb fat ratio
Enhanced growth hormone and IGF-1 levels
Targeted visceral fat reduction without affecting subcutaneous fat
Improved abdominal circumference measurements

Mechanism of Action

Tesamorelin binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, specifically on somatotroph cells. This binding activates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which stimulates the synthesis and release of endogenous growth hormone. The released growth hormone then binds to growth hormone receptors in adipose tissue, activating hormone-sensitive lipase and promoting lipolysis, particularly in visceral fat deposits.

Key Action:

Proven Results

%
Maximum Weight Loss
Clinical research data
0%
Diabetes Risk Reduction
Clinical research data
1,459
Total Participants
Research studies
0%
CV Risk Reduction
Clinical data

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.